ISIS Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 107   

Articles published

ISIS 60.37 +2.03 (3.48%)
price chart
Investor Insights on Isis Pharmaceuticals Inc. (NASDAQ:ISIS)
[ZACKS] Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)(TREND ANALYSIS), This is because this security in the pharmaceutical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Mid Cap Stocks Investor's Alert - ISIS Pharmaceuticals, Inc. (ISIS ...  Techsonian (press release)
Morning's Trade Significant Moves - Noble Energy, (NYSE:NBL), Isis ...
Noble Energy, Inc., an independent energy company, engages in the acquisition, exploration, and production of crude oil, natural gas, and natural gas liquids worldwide.
Trade-Ideas: ISIS Pharmaceuticals (ISIS) Is Today's Post-Market Leader Stock
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform.
Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results ...
Isis Pharmaceuticals� is a registered trademark of Isis Pharmaceuticals, Inc. Akcea Therapeutics� is a trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics� is a trademark of Regulus Therapeutics Inc. KYNAMRO� is a registered trademark of ...
ISIS Pharmaceuticals Given a $88.00 Price Target by Needham & Company LLC ...
ISIS Pharmaceuticals logo Stock analysts at Needham & Company LLC set a $88.00 price target on shares of ISIS Pharmaceuticals (NASDAQ:ISIS) stock in a report issued on Monday. The firm currently has a a �buy� rating on the stock. Needham & Company ...
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
CARLSBAD, Calif., April 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder.
Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With ...
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners.
Isis Pharma (ISIS) Reports Positive Data from OLE Study of ISIS-TTR Rx  StreetInsider.com
Isis Pharmaceuticals ISIS-TTR Effective in Extension Study
According to Isis Pharma, FAP affects over 10,000 patients around the world and no drug has yet been approved by the FDA for its treatment.
Shares of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) Sees Large Outflow of Money
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) traded higher in the last at $66.35, gaining 1.01 points or 1.55%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-3 ...
Downturn of Stocks: TherapeuticsMD (NYSEMKT:TXMD), Alkermes (NASDAQ ...
2015 UBS Global Healthcare Conference on Tuesday, May 19, 2015 in New York, NY. Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform.